FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Dr Armstrong discusses the FDA approval of olaparib plus abiraterone in patients with BRCA-mutated mCRPC, key efficacy and safety data from the PROpel trial, and where the field of prostate cancer research may be headed in the future.

Related Keywords

North Carolina ,United States ,Andrewj Armstrong ,Ashling Wahner ,Facebook ,Twitter ,Duke Cancer Institute In Durham ,Linkedin ,Duke Cancer Institute ,Onclive State ,Science Summit ,Apple Podcasts ,Google Podcasts ,Amazon Music ,D ,Sc ,Fda Approval Of Olaparib Plus Abiraterone ,Patients With Brca Mutated Metastatic Castration Resistant Prostate Cancer ,Propel Trial ,Nct03732820 ,